Research Square (Research Square),
Год журнала:
2023,
Номер
unknown
Опубликована: Авг. 31, 2023
Abstract
Background
Gastric
cancer
(GC)
is
a
highly
chemoresistant
malignancy
with
poor
prognosis.
Paclitaxel's
low
response
rate
as
second-line
chemotherapy
for
advanced
GC
has
prompted
intensive
research
into
its
molecular
basis
and
prospective
targeted
therapies
to
enhance
therapeutic
efficacy.
The
objective
of
this
study
was
investigate
the
synergistic
effects
NFE2L2
silencing
in
combination
paclitaxel
treatment
on
cell
viability,
apoptosis,
proliferation,
autophagy,
migration.
Methods
After
siRNA-mediated
AGS
cells,
transfection
efficacy
evaluated
by
qRT-PCR.
MTT
assay
then
applied
assess
followed
flow
cytometry
analysis
autophagy
cells
treated
siRNA,
paclitaxel,
or
their
combination.
Thereafter,
migration
measured
using
wound-healing
assay.
Ultimately,
relative
gene
expression
levels
apoptotic
(Bax,
CASP3,
CASP9),
anti-apoptotic
(BCL2),
metastatic
(MMP2),
cycle
(TP53)
genes
were
qRT-PCR
all
experiment
groups
further
therapy.
Results
siRNA
significantly
enhanced
paclitaxel-induced
apoptosis
sensitized
via
modulating
apoptosis-related
including
BCL2,
Bax,
CASP9.
Besides,
synergistically
induced
arrest
at
G2
phase,
promoted
activation,
inhibited
MMP2
downregulation.
Additionally,
TP53,
key
regulator
growth,
upregulated
compared
control
group.
Conclusions
Our
findings
suggest
that
combined
might
represent
promising
strategy
GC,
however
translational
clinical
are
warranted.
Frontiers in Immunology,
Год журнала:
2023,
Номер
14
Опубликована: Март 20, 2023
The
successful
outcomes
of
chimeric
antigen
receptor
(CAR)
T-cell
therapy
in
treating
hematologic
cancers
have
increased
the
previously
unprecedented
excitement
to
use
this
innovative
approach
various
forms
human
cancers.
Although
researchers
put
a
lot
work
into
maximizing
effectiveness
these
cells
context
solid
tumors,
few
studies
discussed
challenges
and
potential
strategies
overcome
them.
Restricted
trafficking
infiltration
tumor
site,
hypoxic
immunosuppressive
microenvironment
(TME),
escape
heterogeneity,
CAR
exhaustion,
severe
life-threatening
toxicities
are
major
obstacles
facing
T-cells.
designs
will
need
go
beyond
traditional
architectures
order
get
over
limitations
broaden
their
applicability
larger
range
malignancies.
To
enhance
safety,
effectiveness,
treatment
modality,
addressing
present
with
wide
variety
engineering
as
well
integrating
several
therapeutic
tactics.
In
study,
we
reviewed
antigens
that
T-cells
been
clinically
trained
recognize,
counterstrategies
therapy,
such
recent
advances
therapies
combination
optimize
clinical
efficacy
tumors.
Cell Communication and Signaling,
Год журнала:
2023,
Номер
21(1)
Опубликована: Фев. 24, 2023
Abstract
Oncolytic
viruses
(OVs)
infect,
multiply,
and
finally
remove
tumor
cells
selectively,
causing
no
damage
to
normal
in
the
process.
Because
of
their
specific
features,
such
as,
ability
induce
immunogenic
cell
death
contain
curative
transgenes
genomes,
OVs
have
attracted
attention
as
candidates
be
utilized
cooperation
with
immunotherapies
for
cancer
treatment.
This
treatment
takes
advantage
most
cells'
inherent
tendency
infected
by
certain
both
innate
adaptive
immune
responses
are
elicited
OV
infection
oncolysis.
can
also
modulate
microenvironment
boost
anti-tumor
responses.
Mesenchymal
stem
(MSC)
gathering
interest
promising
anti-cancer
treatments
address
a
wide
range
cancers.
MSCs
exhibit
tumor-trophic
migration
characteristics,
allowing
them
used
delivery
vehicles
successful,
targeted
isolated
tumors
metastatic
malignancies.
Preclinical
clinical
research
were
reviewed
this
study
discuss
using
MSC-released
novel
method
cancer.
Stem Cell Research & Therapy,
Год журнала:
2022,
Номер
13(1)
Опубликована: Сен. 24, 2022
Abstract
Advancements
in
adoptive
cell
therapy
over
the
last
four
decades
have
revealed
various
new
therapeutic
strategies,
such
as
chimeric
antigen
receptors
(CARs),
which
are
dedicated
immune
cells
that
engineered
and
administered
to
eliminate
cancer
cells.
In
this
context,
CAR
T-cells
shown
significant
promise
treatment
of
hematological
malignancies.
However,
many
obstacles
limit
efficacy
T-cell
both
solid
tumors
Consequently,
CAR-NK
CAR-M
therapies
recently
emerged
novel
options
for
addressing
challenges
associated
with
therapies.
Currently,
trials
underway
human
malignancies
around
world
improve
antitumor
activity
reduce
toxicity
therapy.
This
review
will
describe
comprehensive
literature
recent
findings
on
a
wide
range
malignancies,
well
years.
Cancer Cell International,
Год журнала:
2023,
Номер
23(1)
Опубликована: Фев. 10, 2023
Abstract
After
skin
malignancy,
breast
cancer
is
the
most
widely
recognized
detected
in
women
United
States.
Breast
(BCa)
can
happen
all
kinds
of
people,
but
it's
much
more
common
women.
One
four
cases
and
one
six
deaths
due
to
are
related
cancer.
Angiogenesis
an
essential
factor
growth
tumors
metastases
various
malignancies.
An
expanded
level
angiogenesis
diminished
endurance
BCa
patients.
This
function
assumes
a
fundamental
part
inside
human
body,
from
beginning
phases
life
dangerous
malignancy.
Various
factors,
referred
as
angiogenic
work
make
new
capillary.
Expanding
proof
demonstrates
that
managed
by
microRNAs
(miRNAs),
which
small
non-coding
RNA
with
19–25
nucleotides.
MiRNA
post-transcriptional
regulator
gene
expression
controls
many
critical
biological
processes.
Endothelial
miRNAs,
angiomiRs,
probably
concerned
tumor
improvement
via
regulation
pro-and
anti-angiogenic
factors.
In
this
article,
we
reviewed
therapeutic
functions
miRNAs
angiogenesis,
several
novel
delivery
carriers
for
miRNA-based
therapeutics,
well
CRISPR/Cas9
targeted
therapy
Cell Biology International,
Год журнала:
2024,
Номер
unknown
Опубликована: Окт. 4, 2024
Abstract
Since
suppressor/enhancer
of
Lin‐12‐like
(SEL1L)
was
cloned
in
1997,
various
pieces
evidence
from
lower
species
suggest
it
plays
a
significant
role
protein
degradation
via
the
ubiquitin‐proteasome
system.
The
relevance
SEL1L
many
aspects
malignant
transformation
and
tumorigenic
events
has
been
subject
research,
which
shown
compelling
vitro
vivo
findings
relating
its
altered
expression
to
changes
tumor
aggressiveness.
Endoplasmic
Reticulum
(ER)
cells
is
crucial
for
preserving
cellular
proteostasis
by
inducing
unfolded
response
(UPR),
stress
response.
A
component
UPR
ER‐associated
(ERAD),
guards
against
ER
stress‐induced
apoptosis
removal
or
misfolded
proteins
As
stabilizer
HMG‐CoA
reductase
1
(HRD1),
one
main
components
ERAD,
an
important
homeostasis.
Notably,
levels
these
two
fluctuate
independently
cancer
types,
yet
their
affect
other
associated
during
pathogenesis.
Recent
studies
have
also
outlined
function
medication
resistance.
This
review
explores
value
targeting
as
novel
treatment
approach
cancer,
focusing
on
molecular
processes
involvement
etiology.
Cell Communication and Signaling,
Год журнала:
2023,
Номер
21(1)
Опубликована: Ноя. 9, 2023
Abstract
Beyond
the
encouraging
results
and
broad
clinical
applicability
of
immune
checkpoint
(ICP)
inhibitors
in
cancer
therapy,
ICP-based
immunotherapies
context
autoimmune
disease,
particularly
multiple
sclerosis
(MS),
have
garnered
considerable
attention
hold
great
potential
for
developing
effective
therapeutic
strategies.
Given
well-established
immunoregulatory
role
ICPs
maintaining
a
balance
between
stimulatory
inhibitory
signaling
pathways
to
promote
tolerance
self-antigens,
dysregulated
expression
pattern
has
been
observed
significant
proportion
patients
with
MS
its
animal
model
called
experimental
encephalomyelitis
(EAE),
which
is
associated
autoreactivity
towards
myelin
neurodegeneration.
Consequently,
there
rationale
immunotherapeutic
strategies
induce
while
suppressing
ICPs,
including
engineering
cells
overexpress
ligands
ICP
receptors,
such
as
program
death-1
(PD-1),
or
designing
fusion
proteins,
namely
abatacept,
bind
inhibit
co-stimulatory
involved
overactivated
T-cell
mediated
autoimmunity,
other
that
will
be
discussed
in-depth
current
review.
Research Square (Research Square),
Год журнала:
2023,
Номер
unknown
Опубликована: Июнь 28, 2023
Abstract
Background:
Gastric
cancer
(GC)
is
a
highly
chemoresistant
malignancy
with
poor
prognosis.
Paclitaxel's
low
response
rate
as
second-line
chemotherapy
for
advanced
GC
has
prompted
intensive
research
into
its
molecular
basis
and
prospective
targeted
therapies
to
enhance
therapeutic
efficacy.
The
objective
of
this
study
was
investigate
the
synergistic
effects
NRF2
silencing
in
combination
paclitaxel
treatment
on
cell
viability,
apoptosis,
proliferation,
autophagy,
migration.
Methods:
After
siRNA-mediated
AGS
cells,
transfection
efficacy
evaluated
by
qRT-PCR.
MTT
assay
then
applied
assess
followed
flow
cytometry
analysis
autophagy
cells
treated
siRNA,
paclitaxel,
or
their
combination.
Thereafter,
migration
measured
using
wound-healing
assay.
Ultimately,
relative
gene
expression
levels
apoptotic
(Bax,
Caspase-3,
Caspase-9),
anti-apoptotic
(Bcl-2),
metastatic
(MMP-2),
cycle
(P53)
genes
were
qRT-PCR
all
experiment
groups
further
therapy.
Results:
siRNA
significantly
enhanced
paclitaxel-induced
apoptosis
sensitized
via
modulating
apoptosis-related
including
Bcl-2,
Bax,
Caspase-9.
Besides,
synergistically
induced
arrest
at
G2
phase,
promoted
activation,
inhibited
MMP-2
downregulation.
Additionally,
P53,
key
regulator
growth,
upregulated
compared
control
group.
Conclusions:
Our
findings
suggest
that
combined
might
represent
promising
strategy
GC,
however
translational
clinical
are
warranted.
